GRAIL, Inc. ( GRAL ) 2026 UBS Global Healthcare Conference November 10, 2026 11:00 AM EST
Company Participants
Aaron Freidin - CFO & Head of Corporate Development
Conference Call Participants
Douglas Schenkel - UBS Investment Bank, Research Division
Presentation
Douglas Schenkel
UBS Investment Bank, Research Division
All right. Good morning. I'm Doug Schenkel. It's my pleasure to welcome Aaron Frieden, CFO of GRAIL. Aaron, thank you for being here.
Aaron Freidin
CFO & Head of Corporate Development
Yes. Thanks for having us, Doug.
Question-and-Answer Session
Douglas Schenkel
UBS Investment Bank, Research Division
So as GRAILS's test Gelleri moves through FDA review. The key debate is really what approval could unlock from a reimbursement perspective, how important that is to driving broader adoption and how this positions you and others more broadly in the context of multi-cancer screening. It is a massive opportunity. It could make a huge difference for the general population in the U.S.…